Ovid Therapeutics Inc.

NasdaqGS:OVID 株式レポート

時価総額:US$74.6m

Ovid Therapeutics 配当と自社株買い

配当金 基準チェック /06

Ovid Therapeutics配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-0.9%

バイバック利回り

総株主利回り-0.9%
将来の配当利回り0%
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 09

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Nov 10
We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Jun 27
Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Mar 13
Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Sep 09
Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04

Aug 09

We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Jun 09
We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Ovid Therapeutics: Good Entry Point For Investors

Jun 18

Ovid Therapeutics appoints Jeff Rona as CFO

Jun 04

Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Apr 16
Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Mar 20
Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Mar 18
Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Mar 01
We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Jan 25
Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Revisiting Ovid Therapeutics

Jan 14

Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Dec 21
Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Ovid Therapeutics misses goal in Angelman syndrome treatment

Dec 01

決済の安定と成長

配当データの取得

安定した配当: OVIDの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: OVIDの配当金が増加しているかどうかを判断するにはデータが不十分です。


配当利回り対市場

Ovid Therapeutics 配当利回り対市場
OVID 配当利回りは市場と比べてどうか?
セグメント配当利回り
会社 (OVID)n/a
市場下位25% (US)1.3%
市場トップ25% (US)4.2%
業界平均 (Biotechs)2.3%
アナリスト予想 (OVID) (最長3年)0%

注目すべき配当: OVIDは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: OVIDは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。


株主への利益配当

収益カバレッジ: OVIDの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。


株主配当金

キャッシュフローカバレッジ: OVIDが配当金を報告していないため、配当金の持続可能性を計算できません。


高配当企業の発掘